Strategies for low-molecular-weight heparin management in pregnant women with mechanical prosthetic heart valves: A nationwide survey of Dutch practice
2022

Managing Heparin in Pregnant Women with Heart Valves

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): Voortman Marco, Roos Jolien W., Slomp Jennichjen, van Dijk Arie P.J., Bouma Berto J., Sieswerda Gertjan T.J., Kiès Philippine, Boer Anna, Waskowsky Willem M., von Birgelen Clemens

Primary Institution: Medisch Spectrum Twente

Hypothesis

How can the management of low molecular weight heparin (LMWH) treatment in pregnant women with mechanical prosthetic heart valves be optimized?

Conclusion

There is considerable variation in LMWH management for pregnant women with mechanical prosthetic heart valves in Dutch clinical practice.

Supporting Evidence

  • All centers monitored weekly peak anti-Xa levels throughout pregnancy.
  • Four out of 8 centers monitored additional trough anti-Xa levels.
  • Six of the 8 centers formulated local practice guidelines for changing LMWH doses.

Takeaway

Doctors in the Netherlands use different methods to give blood thinners to pregnant women with heart valves, and they need to agree on a better way to do it.

Methodology

A survey was conducted among Dutch congenital cardiologists of tertiary centers to evaluate LMWH treatment practices.

Limitations

The study did not collect specific characteristics of respondents or the centers, which may limit the generalizability of the findings.

Participant Demographics

Participants were ACHD cardiologists from 8 different tertiary centers in the Netherlands.

Digital Object Identifier (DOI)

10.1016/j.ijcchd.2022.100373

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication